Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT Study | Zendy

HansJürgen Stellbrink | Zendy; Chloe Orkin | Zendy; José Ramón Arribas | Zendy; Juliet Compston | Zendy; Jan Gerstoft | Zendy; Eric Van Wijngaerden | Zendy; Adriano Lazzarin | Zendy; Giuliano Rizzardini | Zendy; Herman G. Sprenger | Zendy; John S. Lambert | Zendy; Gunta Stūre | Zendy; David Leather | Zendy; Sara Hughes | Zendy; Patrizia Zucchi | Zendy; Helen Pearce | Zendy

Open Access

Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT Study

Author(s) -

HansJürgen Stellbrink,

Chloe Orkin,

José Ramón Arribas,

Juliet Compston,

Jan Gerstoft,

Eric Van Wijngaerden,

Adriano Lazzarin,

Giuliano Rizzardini,

Herman G. Sprenger,

John S. Lambert,

Gunta Stūre,

David Leather,

Sara Hughes,

Patrizia Zucchi,

Helen Pearce

Publication year - 2010

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/656417

Subject(s) - emtricitabine , abacavir , lamivudine , medicine , gastroenterology , pharmacology , virology , hepatitis b virus , virus

Abacavir-lamivudine and tenofovir DF-emtricitabine fixed-dose combinations are commonly used as first-line antiretroviral therapies. However, few studies have comprehensively compared their relative safety profiles.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research